mirvetuximab soravtansine
Elahere Fully Approved for Certain Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The FDA approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult ...
MARCH 25, 2024
OS Benefit in Platinum-Resistant Ovarian Cancer Shown for First Time
For the first time in a multicenter phase 3 trial, an overall survival (OS) benefit was provided by one therapy ...
JULY 10, 2023
Load more